Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)

Completed · Phase 2/Phase 3

Conditions studied: Choroidal Neovascularization, Age-Related Macular Degeneration

In brief

Randomized controlled clinical trial of periocular corticosteroids as adjunctive therapy to photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration (AMD). Patients undergoing PDT are randomized to either a periocular corticosteroid injection with 40 mg of triamcinolone acetonide or observation just prior to PDT. Patients are followed for 6 months. Primary outcome is leakage from choroidal neovascularization (CNV) at 3 months on fluorescein angiography.

Key facts

Study ID

NCT00305630

Run by

Johns Hopkins University

People needed

100

Starts

2002-07-01

Expected to finish

2005-11-01

Last updated by the study team

2006-03-22

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Active choroidal neovascularization
• Age related macular degeneration
• Visual acuity 20/20 to 20/400

You may not qualify if…

• Neovascular lesion >6500 microns is greatest linear diameter
• More than one prior photodynamic therapy treatment
• Receiving systemic corticosteroids
• Intraocular pressure > 21 mm Hg or glaucoma medication use
• History of glaucoma or history of ocular hypertension

Where it is running

• Johns Hopkins Univeristy School of Medicine — Baltimore, Maryland, United States
• Oregon Health Science Univeristy — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.